Stone X Group Inc. Clarus Therapeutics Holdings, Inc. Transaction History

Stone X Group Inc.

  • $2.06 Trillion
  • Q2 2025

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 13, 2025
BUY
N/A
11,685 New
11,685 $4.47 Million

About Clarus Therapeutics Holdings, Inc.

CRXT Quotes by TradingView
  • Ticker CRXT
  • Exchange NASDAQ
  • Shares Outstandng 52,020,700
  • Market Cap $652
  • Description
  • Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for pr...
More about CRXT
Track This Portfolio

Track Stone X Group Inc. Portfolio

Follow Stone X Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email